Edgewise Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D.

Edgewise Therapeutics, Inc.’s own tally for this item (“Elect Director: Badreddin Edris, Ph.D.”): 64,082,681 for, 27,041,013 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of three Class II Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 9,011,914 for, 6,001,421 withheld, 4,004,741 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Jonathan Root, M.D.

Edgewise Therapeutics, Inc.’s own tally for this item (“Elect Director: Jonathan Root, M.D.”): 59,213,781 for, 31,909,913 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of three Class II Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 8,037,314 for, 6,975,782 withheld, 4,004,981 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Laura Brege

Edgewise Therapeutics, Inc.’s own tally for this item (“Elect Director: Laura Brege”): 87,300,827 for, 3,822,867 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of three Class II Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 17,565,125 for, 1,411,741 withheld, 41,210 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: CONDUCT AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Edgewise Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on the Compensation of the Company's Named Executive Officers”): 87,055,111 for, 3,491,326 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 71 managers: 16,964,741 for, 2,003,771 against, 4,800 withheld, 31,644 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 195 managers: 76,581,327 for, 2,805,542 against, 61 abstained, 370 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFY THE SELECTION OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Edgewise Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 99,637,228 for, 1,123 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 18,965,101 for, 31,644 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.